OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML

By afschroeder • July 29, 2026

Borate UM, Huang Y, Lin TL, Handa S, Swords R, Lachowiez CA, Traer E, Stock W, Odenike O, Patel AA, Baer MR, Duong VH, Stein EM, Blum W, Vale CA, Curran E, Madanat YF, Olin RL, Schiller GJ, Nichols AD, Williams L, Heerema NA, Johnson MF, Chen TL, Marcus S, Martycz M, Stefanos M, Rosenberg L, DeGennaro LJ, Gruenbaum L, Burd A, Byrd JC, Druker BJ, Levine RL, Yocum AO, Mims AS, Zeidner JF. OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML. Blood. 2026 Jul 28:blood.2026034611. doi: 10.1182/blood.2026034611. Epub ahead of print. PMID: 42520193.

Tags: Hematology/Oncology, Publications

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004

Wierda WG, Dorritie KA, Gauthier J, Nath R, Kipps TJ, Riedell PA, Eradat HA, Kenderian SS, Kharfan-Dabaja MA, Shah NN, Solomon SR, Stephens DM, Ermann[...]

Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis

Early detection and localization of recurrent prostate cancer using [Formula: see text]F-DCFPyL PET/CT in patients with low and ultra-low PSA levels

Sonni I, Gulpe A, Nickols NG, Schaffer D, Montagut L, Berenji GR, Rettig MB. Early detection and localization of recurrent prostate cancer using [Formula: see[...]